Background and rationale:
The range of treatment options for myeloma has changed dramatically over the last decade. In addition, a large number of second-generation and targeted therapies are under development, expanding the repertoire of agents that are likely to be available in the future. However, the optimal way to utilize these therapies, including combination of agents and treatment algorithms, is yet to be defined. Although there have been improved outcomes following the introduction of newer agents, the median survival for myeloma is only 4-5 years with current therapy. As such, novel therapeutic approaches are required to improve patient outcomes.